The acquisition of Scorpion's PI3Kα inhibitor program by Eli Lilly is a strategic move to strengthen its oncology pipeline. The inclusion of STX-478, which is in Phase 1/2 trials, could potentially address a significant portion of hormone-positive breast cancer cases. This acquisition aligns with Lilly's ongoing efforts in cancer treatment, likely leading to positive investor sentiment and a potential short-term stock price increase.